Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 5Gynecologic 1Classical hematology 1Breast 1

Conditions

Uterine Cervical Neoplasms 3Uterine Cervical Dysplasia 1Thrombocytopenia 1Precancerous Conditions 1Pathologic Complete Response 1Ovarian Neoplasms 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 19Paclitaxel 10Carboplatin 10Magnetic Resonance Spectroscopy 9Docetaxel 9Cyclophosphamide 9Specimen Handling 8Cisplatin 8Gemcitabine 7Drug Therapy 7sargramostim 6Pemetrexed 6Nivolumab 6fludarabine 5aldesleukin 5Trastuzumab 5Bevacizumab 5Taxes 4Fluorouracil 4Blood Specimen Collection 4Amifostine 4veliparib 3pegfilgrastim 3Topotecan 3Irinotecan 3IFL protocol 3Fluorodeoxyglucose F18 3Etoposide 3Early Intervention, Educational 3tariquidar 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Tretinoin × Gynecologic × Clear all
NCT07586826 2026-05-14

N01-A-PICIT-GT

Peking University People's Hospital

Phase 2 Recruiting
220 enrolled
BreastClassical hematologyGynecologicThoracic

Pathologic Complete Response, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thrombocytopenia, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡